Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model
Abstract Persistent infection with high-risk genotypes of human papillomavirus (HPV) is the leading cause of cervical cancer. The HPV oncoprotein E7 is constitutively expressed in cervical cancer and considered as an essential target for tumor-specific immunity. The goal of this study was to develop...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Infectious Agents and Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13027-021-00346-7 |
id |
doaj-a213db6f1d4144389a194dab6e6a2723 |
---|---|
record_format |
Article |
spelling |
doaj-a213db6f1d4144389a194dab6e6a27232021-01-31T12:16:16ZengBMCInfectious Agents and Cancer1750-93782021-01-0116111010.1186/s13027-021-00346-7Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse modelFariba Dorostkar0Arash Arashkia1Farzin Roohvand2Zabihollah Shoja3Mohsen Navari4Maryam Mashhadi Abolghasem Shirazi5Zahra Shahosseini6Mohammad Farahmand7Mohammad Sadegh Shams nosrati8Somayeh Jalilvand9Department of Virology, School of Public Health, Tehran University of Medical SciencesDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Medical Biotechnology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical SciencesDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Virology, School of Public Health, Tehran University of Medical SciencesDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Virology, School of Public Health, Tehran University of Medical SciencesAbstract Persistent infection with high-risk genotypes of human papillomavirus (HPV) is the leading cause of cervical cancer. The HPV oncoprotein E7 is constitutively expressed in cervical cancer and considered as an essential target for tumor-specific immunity. The goal of this study was to develop a candidate therapeutic vaccine based on the mutated E7 protein that had possibly reduced transformation capacity while was able to elicit a robust immune response. Therefore, the mutant type of HPV 16 E7 (E7GRG) protein was recombinantly expressed in E. coli. The protein was then purified and formulated with 2’-3’cGAMP CDN and/or CpG-C ODN adjuvants and subcutaneously injected to female C57BL/6 mice. To evaluate the immunogenic response, lymphocyte proliferation, secretion levels of IFN-γ and IL-4 cytokines, granzyme B level, and total IgG and subclasses of IgG antibody were measured. The anti-tumor activity was evaluated in tumor-harboring C57BL/6 mice. The highest rate of cell proliferation, IFN-γ and granzyme B levels, and amount of IgG antibody were found in mice group that were injected by E7GRG + 2′-3′cGAMP + CpG-C. Therapeutic immunization with E7GRG + 2′-3′cGAMP + CpG-C also significantly suppressed TC-1 tumor growth in mice. In conclusion, the results demonstrated that E7GRG + 2′-3′cGAMP + CpG-C induced strong cell-mediated and humoral immune responses that resulted in inhibition of tumor in mouse model.https://doi.org/10.1186/s13027-021-00346-7Human papillomavirusHPV vaccineE7 oncoproteinStimulator of interferon genesSTINGCpG ODN 2395 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fariba Dorostkar Arash Arashkia Farzin Roohvand Zabihollah Shoja Mohsen Navari Maryam Mashhadi Abolghasem Shirazi Zahra Shahosseini Mohammad Farahmand Mohammad Sadegh Shams nosrati Somayeh Jalilvand |
spellingShingle |
Fariba Dorostkar Arash Arashkia Farzin Roohvand Zabihollah Shoja Mohsen Navari Maryam Mashhadi Abolghasem Shirazi Zahra Shahosseini Mohammad Farahmand Mohammad Sadegh Shams nosrati Somayeh Jalilvand Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model Infectious Agents and Cancer Human papillomavirus HPV vaccine E7 oncoprotein Stimulator of interferon genes STING CpG ODN 2395 |
author_facet |
Fariba Dorostkar Arash Arashkia Farzin Roohvand Zabihollah Shoja Mohsen Navari Maryam Mashhadi Abolghasem Shirazi Zahra Shahosseini Mohammad Farahmand Mohammad Sadegh Shams nosrati Somayeh Jalilvand |
author_sort |
Fariba Dorostkar |
title |
Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model |
title_short |
Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model |
title_full |
Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model |
title_fullStr |
Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model |
title_full_unstemmed |
Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model |
title_sort |
co‐administration of 2’3’-cgamp sting activator and cpg-c adjuvants with a mutated form of hpv 16 e7 protein leads to tumor growth inhibition in the mouse model |
publisher |
BMC |
series |
Infectious Agents and Cancer |
issn |
1750-9378 |
publishDate |
2021-01-01 |
description |
Abstract Persistent infection with high-risk genotypes of human papillomavirus (HPV) is the leading cause of cervical cancer. The HPV oncoprotein E7 is constitutively expressed in cervical cancer and considered as an essential target for tumor-specific immunity. The goal of this study was to develop a candidate therapeutic vaccine based on the mutated E7 protein that had possibly reduced transformation capacity while was able to elicit a robust immune response. Therefore, the mutant type of HPV 16 E7 (E7GRG) protein was recombinantly expressed in E. coli. The protein was then purified and formulated with 2’-3’cGAMP CDN and/or CpG-C ODN adjuvants and subcutaneously injected to female C57BL/6 mice. To evaluate the immunogenic response, lymphocyte proliferation, secretion levels of IFN-γ and IL-4 cytokines, granzyme B level, and total IgG and subclasses of IgG antibody were measured. The anti-tumor activity was evaluated in tumor-harboring C57BL/6 mice. The highest rate of cell proliferation, IFN-γ and granzyme B levels, and amount of IgG antibody were found in mice group that were injected by E7GRG + 2′-3′cGAMP + CpG-C. Therapeutic immunization with E7GRG + 2′-3′cGAMP + CpG-C also significantly suppressed TC-1 tumor growth in mice. In conclusion, the results demonstrated that E7GRG + 2′-3′cGAMP + CpG-C induced strong cell-mediated and humoral immune responses that resulted in inhibition of tumor in mouse model. |
topic |
Human papillomavirus HPV vaccine E7 oncoprotein Stimulator of interferon genes STING CpG ODN 2395 |
url |
https://doi.org/10.1186/s13027-021-00346-7 |
work_keys_str_mv |
AT faribadorostkar coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel AT arasharashkia coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel AT farzinroohvand coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel AT zabihollahshoja coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel AT mohsennavari coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel AT maryammashhadiabolghasemshirazi coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel AT zahrashahosseini coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel AT mohammadfarahmand coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel AT mohammadsadeghshamsnosrati coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel AT somayehjalilvand coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel |
_version_ |
1724317425651941376 |